Scarica l'app Stockscreener
44.91
7.59%
3.17
Dopo l'orario di chiusura:
44.50
-0.41
-0.91%
Exact Sciences Corp Borsa (EXAS) Ultime notizie
Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know - uk.finance.yahoo.com
The Top 5 Analyst Questions From Exact Sciences’s Q2 Earnings Call - Yahoo Finance
Exact Sciences price target lowered to $60 from $65 at BTIG - TipRanks
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up - Yahoo Finance
BTIG lowers Exact Sciences stock price target to $60 on Freenome deal - Investing.com
EXAS Q2 Deep Dive: Portfolio Expansion and Productivity Drive Guidance Increase Amid Market Caution - Yahoo Finance
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock - Yahoo Finance
Multi Cancer Early Detection Market Forecast Report 2025-2033: A $4.3 Billion Market by 2033, as Market Set to Quadruple from $1 Billion Valuation in 2024 - Yahoo Finance
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Benzinga
FY2025 EPS Forecast for Exact Sciences Increased by Analyst - Defense World
Applying Elliott Wave Theory to Exact Sciences CorporationEarnings Impact and Stock Reaction Analysis - Newser
How to read the order book for Exact Sciences CorporationFree Real Time Alerts Based on AI Prediction - Newser
Real time social sentiment graph for Exact Sciences CorporationAI Entry Timing Prediction for Swing Traders - Newser
Real time scanner hits for Exact Sciences Corporation explainedTrading Volume Anomaly Summary and Insight - Newser
Cathie Wood Buys Alphabet, Exact Sciences Amid Market Volatility - WebProNews
Avantax Advisory Services Inc. Acquires 1,259 Shares of Exact Sciences Corporation (NASDAQ:EXAS) - Defense World
Leerink Partnrs Forecasts Weaker Earnings for Exact Sciences - Defense World
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $60 to $70 - 富途牛牛
Exact Sciences Corporation (NASDAQ:EXAS) Q2 2025 Earnings Call Transcript - Insider Monkey
Cathie Wood’s ARK bolsters Exact Sciences, sheds DraftKings stock By Investing.com - Investing.com Australia
Cathie Wood’s ARK bolsters Exact Sciences, sheds DraftKings stock - Investing.com
Exact Sciences (NASDAQ:EXAS) Hits New 1-Year Low Following Analyst Downgrade - Defense World
Exact Sciences Corp’s Strong Earnings Call Highlights - TipRanks
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst - AOL.com
Is Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal? - Investor's Business Daily
Why Is Exact Sciences Stock Tumbling Thursday?Exact Sciences (NASDAQ:EXAS) - Benzinga
Exact Sciences Earnings: Blood-Based Test Misses Cutoff for Medicare Reimbursement - Morningstar
Exact Sciences Leads the Colorectal Cancer Screening Market, but Uncertainty Lies Ahead - Morningstar
Exact Sciences stock price target lowered to $46 at RBC on growth concerns - Investing.com Canada
Bernstein SocGen lowers Exact Sciences stock price target to $60 - Investing.com
Exact Sciences (EXAS) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Exact Sciences (EXAS) Secures Rights to Freenome's Cancer Screening Tests - GuruFocus
UBS Adjusts Exact Sciences Price Target to $53 From $61, Maintains Neutral Rating - MarketScreener
Research Alert: CFRA Lowers View On Shares Of Exact Sciences Corporation To Hold From Buy - 富途牛牛
Exact Sciences stock price target lowered to $66 by TD Cowen after blood test setback - Investing.com
Piper Sandler reiterates Overweight rating on Exact Sciences stock By Investing.com - Investing.com Canada
Piper Sandler reiterates Overweight rating on Exact Sciences stock - Investing.com
Exact Sciences Reports Strong Q2 2025 Revenue GrowthNews and Statistics - IndexBox
Exact Sciences Corp. Exceeds Q2 Earnings ExpectationsNews and Statistics - IndexBox
Exact Sciences price target lowered to $55 from $65 at Barclays - TipRanks
Exact Sciences Q2 2025 Earnings Call Transcript - MarketBeat
Exact Sciences to acquire US rights for Freenome’s blood-based CRC test - Yahoo Finance
Exact Sciences: Q2 Earnings Snapshot - Manistee News Advocate
Earnings call transcript: Exact Sciences Q2 2025 beats EPS forecasts - Investing.com
Exact Sciences Q2 2025 slides: Revenue jumps 16%, guidance raised on strong performance - Investing.com Canada
Exact Sciences Corp. Reports Strong Q2 2025 Results - TipRanks
Exact Sciences lays off 4% of company including Madison positions - WMTV 15 NEWS
Freenome Announces Exclusive License Agreement with Exact Sciences to Commercialize Freenome's Blood-Based Screening Test for Colorectal Cancer | Newswise - Newswise
Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
Exact Sciences (EXAS) Q2 Revenue Up 16% - The Globe and Mail
Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2% - Yahoo Finance
EXACT SCIENCES CORP SEC 10-Q Report - TradingView
Exact Sciences Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Exact Sciences shares plunge despite earnings beat By Investing.com - Investing.com Nigeria
Key External Factors That Drive Exact Sciences Corporation Stock Price MovementsReal Stock Picks With Setup Verification - Newser
Exact Sciences shares plunge despite earnings beat - Investing.com
EXACT Sciences earnings beat by $0.12, revenue topped estimates - Investing.com
Exact Sciences Announces Collaboration with Freenome Holdings - TipRanks
3.96%
1.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):